

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : WenjinYang. Examiner: TBA
Serial No.: TBA Art Unit: TBA
Filed: December 10, 2003
For: ASPARTYL PROTEASE INHIBITORS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:


- ☒ An *original* Information Disclosure Statement; or
☐ A *supplemental* Information Disclosure Statement.

Certificate of Express Mailing

"Express Mail" mailing label number EV 170393580 US

Date of Deposit: December 10, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service as "*Express Mail Post Office to Address*" service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



Signature

Kathy Hart Gagnon

Typed Name

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

- ☒ Pursuant to 37 CFR § 1.97(b); no fee or certification is required:
 - ☒ Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
 - ☐ Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
 - ☐ Before the mailing of a first Office action on the merits; or
 - ☐ Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.
- ☐ Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:
 - ☐ Certifies that *either*:
 - ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
 - ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making

reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; or

☐ Includes herewith the fee set forth in § 1.17(p).

☐ Pursuant to 37 CFR § 1.97(d), after the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *both*:

☐ Certifies that *either*:

☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; and

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- ☒ A copy of each cited reference not indicated with an asterisk is included;
- ☒ Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

| Serial Number | Filing Date | Status |
|---------------|---------------|---------|
| 10/462,127 | June 16, 2003 | Pending |

- ☐ Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

- ☒ Does not contain non-English language citations;
- ☐ Does contain non-English language citations, of which the following is a concise explanation:

[] Includes one or more translations of a non-English citation.

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .


The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,



Nadège M. Lagneau, Ph.D.

Reg. No. 51,908

PATENT GROUP
CHOATE, HALL & STEWART
Exchange Place
53 State Street
Boston, Massachusetts 02109
Tel: (617) 248-5000
Fax: (617) 248-4000

Dated: December 10, 2003

Form PTO-1449
(REV. 8-83)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket:
2004345-0019
(SU-2410 US)

In re Application No.
TBA

**INFORMATION
DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant: Yang, *et al.*

Filing Date:
December 10, 2003

Group:
TBA

U.S. PATENT DOCUMENTS

| Examiner's Initials | U.S. Patent No. | Applicant | Issue Date | Class | Subclass |
|------------------------|-----------------|-----------------------|---------------|-------|----------|
| | *5,196,438 | Martin, <i>et al.</i> | Mar. 23, 1993 | 514 | 311 |
| | *5,413,999 | Vacca, <i>et al.</i> | May 9, 1995 | 514 | 231.5 |
| | *5,585,397 | Tung, <i>et al.</i> | Dec. 17, 1996 | 514 | 473 |
| | *5,728,718 | Randad, <i>et al.</i> | Mar. 17, 1998 | 514 | 357 |
| | | | | | |
| | | | | | |
| | | | | | |

U.S. PATENT APPLICATIONS

| Examiner's Initials: | Serial Number: | Applicant: | Filing Date: | Group: | Art Unit: |
|-------------------------|----------------|------------|--------------|--------|-----------|
| | | | | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials | Document No. | Country | International Publication Date | Translation | |
|------------------------|------------------|-----------|-----------------------------------|-------------|----|
| | | | | Yes | No |
| | ** AU 634756 | Australia | | | |
| | *EP 0 356 223 A2 | Europe | Feb. 2, 1990 | | |
| | EP 0 316 965 A | EU | May 24, 1989 | | |
| | *EP 0 386 611 A2 | Europe | Sep. 12, 1990 | | |
| | *WO 93/02674 | PCT | Feb. 18, 1993 | | |
| | *WO 98/46599 | PCT | Oct. 22, 1998 | | |
| | *WO 00/40558 | PCT | Jul. 13, 2000 | | |
| | WO 00/56335 A | PCT | Mar. 24, 2000 | | |
| | *WO 02/02505 A2 | PCT | Jan. 10, 2002 | | |
| | | | | | |
| | | | | | |

OTHER DOCUMENTS

| | | | | |
|---|--|--|---|------------------------------|
| Form PTO-1449 (REV. 8-83) INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i> | U.S. Department of Commerce Patent and Trademark Office | | Atty. Docket: 2004345-0019 (SU-2410 US) | In re Application No. TBA |
| | Applicant: Yang, <i>et al.</i> | | | |
| | Filing Date: December 10, 2003 | | Group: TBA | |

| Examiner's Initials | Citation (Including Author, Title, Date, Pertinent Pages, Etc.) |
|---------------------|---|
| | *Ajay, <i>et al.</i> , "Designing Libraries with CNS Activity", <i>J. Med. Chem.</i> , 42 :4942-4951, 1999. |
| | Brožková, <i>et al.</i> , "Peptidomimetic Inhibitors of Extracellular Aspartic Proteinases of <i>Candida albicans</i> AND <i>Candida trooicalis</i> ", <i>Collect. Czech. Chem. Commun.</i> , 64 :130-137, 1999. |
| | *Ermolieff, <i>et al.</i> , "Proteolytic Activation of Recombinant Pro-memapsin 2 (Pro- β -secretase) Studied with New Fluorogenic Substrates", <i>Biochemistry</i> , 39 :12450-12456, 2000. |
| | *Haque, <i>et al.</i> , "Potent, Low-Molecular-Weight Non-Peptide Inhibitors of Malarial Aspartyl Protease Plasmepsin II", <i>J. Med. Chem.</i> , 42 : 1428-1440, 1999. |
| | Herrero, <i>et al.</i> , "C-Backbone ranches peptides via reductive amination of cyanomethyleneamino pseudopeptides", <i>Tetrahedron Letters</i> , 43 : 1421-1424, 2002. |
| | *Hussain, <i>et al.</i> , "Identification of a Novel Aspartic Protease (Asp 2) as β -Secretase", <i>Mol. Cell. Neurosci.</i> , 14 :419-427, 1999. |
| | *Sabbagh, <i>et al.</i> , " β -Amyloid and Treatment Opportunities for Alzheimer's Disease", <i>Alz. Dis. Rev.</i> , 3 :1-19, 1997. |
| | *Sinha, <i>et al.</i> , "Purification and cloning of amyloid precursor protein β -secretase from human brain", <i>Nature</i> , 402 :537-540, 1999. |
| | Suárez-Gea, <i>et al.</i> , "Branches Peptides and Conformationally Constrained Analogues form Cyanomethyleneamino Pseudopeptides", <i>Tetrahedron Letters</i> , 37 :2083-2084, 1996. |
| | *Vassar, <i>et al.</i> , " β -Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by Transmembrane Aspartic Protease BACE", <i>Science</i> , 286 :735-741, 1999. |
| | Wolfe, <i>et al.</i> , "A Substrate-Based Difluoro Ketone Selectively Inhibits Alzheimer's γ -Secretase Activity", <i>J. Med. Chem.</i> , 41 :6-9, 1998. |
| | *Yan, <i>et al.</i> , "Membrane-anchored aspartyl protease with Alzheimer's disease β -secretase activity, <i>Nature</i> , 402 :533-537, 1999. |
| | International Search Report issued for PCT application PCT/US03/18858 |

| | |
|---|-----------------|
| EXAMINER | DATE CONSIDERED |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

* Cited in parent application 10/462,127 filed June 16, 2003.

** Patent document cumulative with EP 0 386 611; Issue/publication date unavailable at this time.